Perrigo expands store-brand portfolio in US

Perrigo expands store-brand portfolio in US
A store-brand equivalent to Imodium Multi-Symptom Relief is now available from Perrigo in the US

10 September 2018 - Deborah Wilkes

Perrigo is expanding its offering in the US with a store-brand equivalent to Imodium Multi-Symptom Relief.

The company said it had received final approval from the US Food and Drug Administration (FDA) for the tablets containing 2mg loperamide and 125mg simethicone.

Quoting data from IRI, Perrigo said retail sales of Johnson & Johnson 's Imodium Multi-Symptom Relief over the past 12 months had been around USD62 million.

The product is indicated for relieving symptoms of diarrhoea as well as bloating, cramps, pressure and gas.

Jeff Needham – Perrigo's executive vice president and president, Consumer Healthcare Americas – said the final approval and upcoming launch was an "important accomplishment" for the company's store-brand OTC business.

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE

Click tags below for more information on topics:

Perrigo

Back to Industry News

Share this page: